1. Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis. Issue 1 (7th September 2021) Authors: Gluais‐Dagorn, Pascale; Foretz, Marc; Steinberg, Gregory R.; Batchuluun, Battsetseg; Zawistowska‐Deniziak, Anna; Lambooij, Joost M.; Guigas, Bruno; Carling, David; Monternier, Pierre‐Axel; Moller, David E.; Bolze, Sebastien; Hallakou‐Bozec, Sophie Journal: Hepatology communications Issue: Volume 6:Issue 1(2022) Page Start: 101 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. (November 2021) Authors: Cusi, Kenneth; Alkhouri, Naim; Harrison, Stephen A; Fouqueray, Pascale; Moller, David E; Hallakou-Bozec, Sophie; Bolze, Sebastien; Grouin, Jean-Marie; Jeannin Megnien, Sophie; Dubourg, Julie; Ratziu, Vlad Journal: Lancet gastroenterology and hepatology Issue: Volume 6:Number 11(2021) Page Start: 889 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗